From the Guidelines
There is no recognized medical definition for the term "tougeo" in standard medical terminology or clinical practice. This word does not appear in medical dictionaries, pharmacopeia, or diagnostic manuals, as evidenced by the lack of mention in studies such as 1 and 1. It is not a recognized medical condition, medication, anatomical structure, physiological process, or diagnostic test. If you're seeking information about a specific medical term, it may be helpful to check the spelling or provide additional context, as this could be a misspelling or a term used in a very specialized or regional context that isn't part of mainstream medical vocabulary. Medical terminology typically derives from Latin or Greek roots and follows specific naming conventions that allow healthcare professionals to communicate precisely about diagnoses, treatments, and anatomical structures. Some studies, such as 1, discuss conditions like Tourette syndrome, which may present with symptoms like chronic cough, but "tougeo" is not mentioned. Similarly, 1 discusses habit cough, tic cough, and psychogenic cough, but again, "tougeo" is not referenced. Given the information available, it's clear that "tougeo" does not have a recognized medical definition or usage in clinical practice.
From the Research
Definition of Toujeo
- Toujeo is a long-acting basal insulin analogue, also known as insulin glargine 300 U/mL, used for the treatment of diabetes mellitus 2, 3, 4, 5, 6.
- It has a more stable and prolonged pharmacokinetic/pharmacodynamic profile than insulin glargine 100 U/mL (Lantus), with a duration of glucose-lowering activity exceeding 24 hours 2.
Medical Use
- Toujeo is approved for the treatment of type 1 and type 2 diabetes in adults 2, 5, 6.
- It is used as a basal insulin therapy option, providing a consistent control of diabetes with a significant reduction in the risk of hypoglycemia, especially at night 3, 4, 5, 6.
Characteristics
- Toujeo has a threefold higher concentration compared to the classical insulin Lantus (100 U/mL) 5.
- Its pharmacokinetic and pharmacodynamic profiles are flatter and longer (more than 24 hours) with a lesser intra-/inter-variability, making them more reproducible 5.
- Toujeo offers the same hypoglycaemic efficacy and safety profile as Lantus, but with a lower risk of hypoglycaemia, especially at night, and a slightly smaller weight gain 5, 6.